Table 1 Baseline data sheet of UBE2S in patients with ovarian cancer
Characteristic | UBE2S expression level | P-value | |
|---|---|---|---|
LOW | HIGH | ||
Total Number | 32 | 149 | Â |
Pathological type, n (%) | Â | Â | 0.560 |
 Clear cell | 2 (1.1%) | 7 (3.9%) |  |
 Endometrial | 4 (2.2%) | 12 (6.6%) |  |
 Mucus | 10 (5.5%) | 39 (21.5%) |  |
 Other | 2 (1.1%) | 4 (2.2%) |  |
 Serous | 14 (7.7%) | 87 (48.1%) |  |
FIGO stage, n (%) |  |  |  < 0.001 |
 I–II | 20 (11%) | 3 (1.7%) |  |
 III–IV | 12 (6.6%) | 146 (80.7%) |  |
Histology grade, n (%) |  |  |  < 0.001 |
 G1–G2 | 25 (13.8%) | 28 (15.5%) |  |
 G3 | 7 (3.9%) | 121 (66.9%) |  |
Ascites, n (%) | Â | Â | 0.103 |
 − | 22 (12.2%) | 76 (42%) |  |
 +  | 10 (5.5%) | 73 (40.3%) |  |
Lymph node metastasis, n (%) | Â | Â | 0.250 |
 − | 25 (13.8%) | 98 (54.1%) |  |
 +  | 7 (3.9%) | 51 (28.2%) |  |
Residual lesion size, n (%) | Â | Â | 0.598 |
 0 | 25 (13.8%) | 125 (69.1%) |  |
 2 | 7 (3.9%) | 24 (13.3%) |  |
Age, mean ± SD | 50.81 ± 10.28 | 54.6 ± 8.92 | 0.036 |
CA125, meidan (IQR) | 459.9 (78.52, 1187.25) | 659.6 (318.2, 1459) | 0.046 |